Kambô for Health & Longevity
Evidence Review created on 11/01/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Kambo, Kampô, Kapum, Sapo, Vacina do Sapo, Frog Vaccine, Toad Vaccine, Phyllomedusa bicolor Secretion, Giant Leaf Frog Secretion, Giant Monkey Frog Secretion, Giant Maki Frog Secretion
Motivation
Kambô is the waxy skin secretion of the giant monkey frog, a tree frog of the Amazon rainforest. In a short ritual, a few small burns are made on the skin and the secretion is rubbed into them, setting off an intense reaction of vomiting, flushing, a rapid heartbeat and facial swelling within minutes. The secretion carries dozens of small hormone-like proteins, including morphine-like compounds, which is why it draws interest far beyond its traditional setting.
Indigenous peoples of the western Amazon have long used kambô to sharpen hunting ability and to ward off illness and bad luck. Over the past two decades it has spread to wellness retreats in Europe, North America and Australia, where it is promoted as a cleanse, a mood aid and an immune tonic. That spread has drawn the attention of doctors, toxicologists and regulators, and its legal status now differs from country to country.
This review examines kambô as a health and longevity practice for proactive adults: its active compounds, the human evidence behind its claimed benefits, its documented harms, the factors that modify both, and the practical, legal and monitoring questions around its use.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
These five sources give a high-level view of kambô from critical, academic, regulatory, scientific-review and practitioner perspectives.
-
Kambo: Frog Poison for Health? - Harriet Hall
A physician’s critical walk-through of a Western kambô ceremony, its claimed benefits and its reported harms, useful as a skeptical counterpoint to practitioner claims.
-
Illegal, occasionally deadly, and not much fun. What is the frog toxin Kambô and why do people use it? - Martin Williams
A balanced academic commentary on how the ritual works, what users report gaining, and why rare severe harms sit alongside mostly positive personal accounts.
-
Kambô – leave it with frogs - Medsafe
New Zealand’s medicines regulator summarizes the secretion’s active compounds, the serious reactions reported, and a local case of blood-vessel inflammation after a ritual.
-
The Amazonian kambô frog Phyllomedusa bicolor (Amphibia: Phyllomedusidae): Current knowledge on biology, phylogeography, toxinology, ethnopharmacology and medical aspects - Nogueira et al., 2022
The most comprehensive scientific review, linking the frog’s biology, the secretion’s peptide chemistry, traditional use and the medical consequences of Western use.
-
“Kambo” Animal Medicine: A Neurobiologist’s Key Tool for Healing & Transforming - Caitlin Thompson
A practitioner’s case for kambô in chronic illness and trauma; the guest earns income from kambô sessions, so the episode represents the proponent view rather than independent evidence.
None of the six prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on kambô; web and on-site searches of each returned no relevant result.
Grokipedia
-
A broad overview spanning indigenous origins, peptide pharmacology, claimed benefits versus evidence gaps, documented deaths, legal status and ethical debates over appropriation and frog harvesting.
Examine
No Examine article on kambô exists.
ConsumerLab
No ConsumerLab article on kambô exists.
Systematic Reviews
One systematic review of kambô exists, and it addresses harms.
-
Kambo Administration and Its Association With Sudden Death: Clinical and Forensic Perspectives From a Systematic Review - Sacco et al., 2025
A systematic review of nine case-based articles on fatal and survived kambô poisonings, highlighting sudden cardiac death, esophageal rupture and pre-existing risk factors.
No systematic review or meta-analysis examines any claimed benefit of kambô, so the claimed-effect side of the trade-off is unrepresented in this section.
Mechanism of Action
Kambô is not a single compound but a mixture of peptide families made in the frog’s skin glands and absorbed quickly through burned skin, as reviews describe (Nogueira 2022; den Brave 2014). The main groups are:
- Dermorphins and deltorphins: highly selective activators of the μ-opioid receptor (the main morphine target) and the δ-opioid receptor (an opioid receptor involved in pain and mood); one dermorphin analog was a potent μ-selective pain reliever in rats (Negri 1992), and a review describes deltorphins as highly δ-selective (Negri 2000).
- Phyllocaerulein: mimics CCK (cholecystokinin, a gut hormone that drives gallbladder and pancreatic secretion and nausea), producing vomiting and bowel cramps.
- Phyllokinin and phyllomedusin: activate bradykinin B2 receptors (receptors that widen blood vessels and make them leaky) and tachykinin NK1 receptors (substance P receptors that trigger vomiting and gut contraction), causing flushing, low blood pressure and swelling.
- Sauvagine: activates CRF receptors (receptors for corticotropin-releasing factor, the hormone that starts the stress-hormone cascade).
- Dermaseptins: membrane-disrupting antimicrobial peptides.
Proponents attribute the after-effects to these peptides acting on immunity, mood and pain. Survey authors note that how far setting and expectation shape the reported well-being remains undetermined (Majić 2021).
No human study has measured its absorption, distribution or clearance; effects span gut, vessels, heart and brain. As peptides, the components are expected to be broken down by peptidases (protein-cutting enzymes) rather than CYP enzymes (cytochrome P450, the liver’s main drug-metabolizing system); intravenous dermorphin had an elimination half-life of 0.76 hours in horses (Robinson 2015).
Historical Context & Evolution
Kambô was originally used by western Amazonian peoples, mainly the Katukina and Kaxinawá, against infection and disease and as a physical and mental invigorator; hunters used it for stamina and luck, as reviews describe (Haddad Junior 2020; den Brave 2014). Rubber tappers in Brazil’s Acre state adopted it; it spread to Brazilian cities, then to Europe, North America and Australia, often alongside ayahuasca (a psychedelic Amazonian brew), per a systematic review and a survey (Sacco 2025; Majić 2021).
Scientific interest grew as Vittorio Erspamer’s Rome group isolated its peptides, a later review recounts (Keppel Hesselink 2018). A 1985 randomized trial found intrathecal (injected into the spinal fluid) dermorphin gave longer post-surgical pain relief than morphine (Basso 1985), yet the same review notes the peptide was never developed further (Keppel Hesselink 2018). Ceruletide, a related frog peptide, entered clinical use as a diagnostic agent of gallbladder and pancreatic function, per a later review (Keppel Hesselink 2020).
Clinical attention grew in the 2010s as case reports of dangerously low blood sodium, liver injury, psychosis (loss of contact with reality) and death accumulated, summarized in a case review (Sacco 2022). Australia now lists kambô in Schedule 10 of its Poisons Standard, which prohibits supply and use (Poisons Standard October 2026), a ban in force since 1 October 2021 (Better Health Channel fact sheet). A practitioner attributes harms to unqualified administrators (Outliyr podcast), while an academic commentary notes serious harms are few relative to the presumably large number of administrations worldwide (Conversation article).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no controlled trial of kambô exists, and the only human outcome data are uncontrolled retrospective surveys from a single research group.
Medium 🟩 🟩
No benefit reaches Medium: no trial and no observational study with a comparison group has measured any health outcome after kambô use.
Low 🟩
Self-Reported Well-Being and Life Satisfaction
In an online survey of 386 users, most reported increased well-being or life satisfaction after kambô; a 22-person questionnaire study from the same Berlin group described persisting effects as mainly positive (Majić 2021; Schmidt 2020). Both are retrospective, self-selected and uncontrolled.
Magnitude: 87.31% of 386 respondents reported an increase in personal well-being or life satisfaction (no control group).
Reduced Alcohol and Drug Use
Many users reported cutting back on alcohol, tobacco and recreational drugs after kambô (Majić 2021). The data are retrospective self-reports from one uncontrolled survey; many respondents also used ayahuasca, and most had changed diet or substance use beforehand as ritual preparation.
Magnitude: Of 75 respondents who named addiction as a motive, 28.00% reported never using the substance again and 64.00% reported using it less often (no control group).
Pain Relief from Isolated Dermorphin
Dermorphin, an opioid peptide of the secretion, relieved post-surgical pain for longer than morphine in a randomized double-blind trial of 150 patients (Basso 1985). The evidence is indirect: one purified peptide injected into the spinal fluid, not the whole secretion applied to burns.
Magnitude: Mean pain relief lasted 8.96 hours longer with intrathecal dermorphin than with intrathecal morphine (43.41 versus 34.45 hours) and 32.62 hours longer than with intramuscular pentazocine (10.79 hours); reported as statistically significant (unlikely to be due to chance), with no confidence interval (the range likely to contain the true effect) reported.
Speculative 🟨
Antimicrobial Activity
A review reports that dermaseptins from the secretion act against bacteria, parasites, protozoa and viruses in cell cultures, with few animal and no human studies (Bartels 2019). The basis is mechanistic only.
Antitumor Activity
Dermaseptin B2 inhibited human tumor cell growth in cultures and slowed prostate tumors grown in mice (van Zoggel 2012). The basis is laboratory and animal data on one purified peptide.
Immune Strengthening
A review notes kambô is known as the “toad vaccine” (Haddad Junior 2020), and weakened immunity was a common motive (Majić 2021). No study has measured an immune outcome; the basis is anecdotal only.
Physical Stamina and Alertness
A review of the ritual describes traditional use by Amazonian hunters to boost stamina, strength and hunting luck (den Brave 2014). No study has measured endurance or alertness after kambô; the basis is anecdotal only.
Benefit-Modifying Factors
- Genetic polymorphisms: No data exist. Variants in OPRM1 (the gene for the μ-opioid receptor) alter responses to opioid drugs and could plausibly alter responses to dermorphin, but this has not been studied for kambô.
- Baseline biomarkers: No study has related any baseline biomarker (for example inflammatory or hormonal markers) to reported benefit; the surveys collected no laboratory data.
- Sex: Survey samples were 60.62% women in Majić 2021 and 45.5% in Schmidt 2020; no sex-stratified analysis of reported benefits exists.
- Pre-existing conditions: Common motives included fatigue, depression, weakened immunity, emotional trauma and addiction (Majić 2021); no study compared outcomes by condition, and frequent ayahuasca co-use confounds attribution.
- Age: Surveyed users averaged 38 years, with first use at about 36 (Majić 2021); no data exist on benefit at the older end of adulthood.
- Expectation and setting: Retrospectively rated conviction of benefit rose from 70.55 to 85.05 (0–100 scale) after first use, and the authors note expectation and setting may shape reported effects (Majić 2021).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no controlled trial of kambô exists, and its harms are documented in case reports, a case-based systematic review and an uncontrolled survey.
Medium 🟥 🟥
No risk reaches Medium: no trial and no observational study with a comparison group has measured any harm of kambô.
Low 🟥
Acute Purging Reaction
Within minutes the peptides cause vomiting, flushing, rapid heartbeat, facial and throat swelling and sometimes fainting, usually settling within an hour (Majić 2021). Ritual users seek this reaction (Conversation article). A case report describes agitation and vomiting persisting nearly a day (Li 2018).
Magnitude: Vomiting 86.53%, rapid heartbeat 67.10%, facial swelling 55.18%, throat swelling 24.35% and loss of consciousness 12.18% of 386 survey respondents (no control group).
Severe Hyponatremia and Seizures
Kambô can trigger SIADH (syndrome of inappropriate antidiuretic hormone secretion: the kidneys retain water and dilute blood sodium). Combined with ritual water drinking, it can cause hyponatremia (low blood sodium), seizures and brain swelling, including one brain death (Leban 2016; Tran 2025).
Magnitude: In a review of 11 published acute poisoning cases, SIADH was present in 5 (45.45%; case series, no control group) (Sacco 2022).
Sudden Cardiac Death
A chronic user with LVH (left ventricular hypertrophy: thickened heart muscle) died suddenly, with deltorphin A detected in his blood (Aquila 2018). A systematic review found few published deaths and named sudden cardiac death and esophageal rupture as concrete dangers that pre-existing risk factors may worsen (Sacco 2025).
Magnitude: Not quantified in available studies. No study has measured incidence, because deaths are known only from case and forensic reports and the number of users is unknown.
Esophageal Rupture
Violent vomiting can tear the esophagus (Boerhaave syndrome: a full-thickness tear of the esophageal wall), letting air and fluid into the chest and causing infection and shock (Robalino Gonzaga 2020; Darlington 2023). Cases have required surgery.
Magnitude: Not quantified in available studies. Only individual case reports exist, so no rate can be estimated.
Toxic Hepatitis
Toxic liver injury, probably related to a kambô ritual, occurred in a Polish patient (Pogorzelska 2017). A case review lists raised liver enzymes in numerous other poisonings and attributes them to a liver-damaging action of the toxins (Sacco 2022).
Magnitude: Not quantified in available studies. The evidence consists of case reports without a known number of exposed users.
Psychosis and Lasting Neuropsychiatric Change
Case reports describe psychosis possibly linked to frequent kambô use and persisting behavioral change after kambô-related hyponatremic seizures (Roy 2018; Jauregui 2025). Two survey respondents reported new psychosis (Majić 2021).
Magnitude: 4.40% of 386 respondents reported new mental or emotional problems after kambô and 1.81% reported lasting mental deterioration (no control group).
Systemic Inflammation, Muscle Breakdown and Kidney Injury
Kambô has been followed by SIRS (systemic inflammatory response syndrome: body-wide inflammation with fever and fast heart rate), acute kidney injury and rhabdomyolysis (muscle breakdown that can injure kidneys) (Alvarez-Boizo 2025; Campodónico 2019). In one cancer patient the reaction mimicked tumor progression (Peleg Hasson 2021).
Magnitude: Not quantified in available studies. Only case reports exist, with creatine kinase (a muscle enzyme) reaching 107,216 IU/L in one seizure-complicated case (no control group).
Immune-Mediated Muscle, Nerve and Blood-Vessel Disorders
Case reports link kambô to dermatomyositis (autoimmune inflammation of muscle and skin) and to acute demyelinating polyneuropathy (immune damage to nerve insulation causing weakness) with residual deficits (de la Vega 2020; Mantilla-Pardo 2026). New Zealand’s adverse-reaction monitoring center received a report of hypersensitivity vasculitis (allergic blood-vessel inflammation) (Medsafe Prescriber Update).
Magnitude: Not quantified in available studies. Each disorder is known only from single case reports.
Delayed Effective Treatment
A traveler’s use of kambô instead of standard care delayed effective treatment of cutaneous leishmaniasis (a parasitic skin infection) (Kuna 2024). Kambô is increasingly used by cancer patients in Europe (Peleg Hasson 2021). This harm arises from substitution, not toxicity.
Magnitude: Not quantified in available studies. Only case reports describe treatment delay, so its frequency is unknown.
Burn-Site Scarring
The ritual burns leave characteristic lasting scars at the application points, as a survey report describes (Majić 2021). Infection of the open burns is plausible but undocumented in the cited reports.
Magnitude: Not quantified in available studies. No study has counted scarring or burn-site infection among users.
Speculative 🟨
Pregnancy Loss
A systematic review notes traditional use of kambô to induce abortion (Sacco 2025). No human outcome data exist; the concern rests on traditional reports and on the peptides’ smooth-muscle and blood-pressure effects.
Mislabeled or Adulterated Secretions
A systematic review warns that inexperienced practitioners may use secretions of other amphibians such as the cane toad (Sacco 2025). Sticks from one forensic case contained kambô peptides (Aquila 2018); the basis is isolated reports.
Risk-Modifying Factors
- Genetic polymorphisms: No pharmacogenetic data exist. Inherited long-QT syndromes (genetic heart-rhythm disorders) and hereditary angioedema (C1-inhibitor deficiency causing recurrent deep swelling) plausibly raise arrhythmia (heart-rhythm disturbance) and airway-swelling risk, given kambô’s effects on heart rate and bradykinin receptors; this is inferred.
- Baseline biomarkers: Low baseline sodium or potassium, a prolonged QTc (corrected QT interval on the electrocardiogram, or ECG, a measure of heart-rhythm recovery) and reduced kidney function plausibly amplify hyponatremia and arrhythmia risk; a case review found low potassium in several poisonings (Sacco 2022).
- Sex: Nine of 11 acute poisoning cases in a case review were women (Sacco 2022), and premenopausal women were more vulnerable to brain injury from hyponatremia after surgery (Ayus 1992). Whether this reflects susceptibility or user demographics is unknown.
- Pre-existing conditions: Coronary disease and LVH preceded the forensic death case (Aquila 2018); depression, personality disorder and substance dependence appear among cases in a case review (Sacco 2022); active cancer preceded a severe inflammatory reaction (Peleg Hasson 2021).
- Age: Surveyed users averaged 38 years (Majić 2021). No data exist for older adults, in whom reduced water excretion, diuretic (drugs that increase urine output) use and undiagnosed heart disease plausibly raise hyponatremia and cardiac risk; this is inferred.
- Water intake and dose: A case review found 3.5–6 liters drunk after application in three cases (Sacco 2022); a practitioner-run review of 147 users linked more application points to more facial swelling and sweating (Thompson 2022).
Key Interactions & Contraindications
Documented interactions:
- Large-volume water intake: Medsafe links kambô hyponatremia to SIADH plus ritual water drinking (Medsafe Prescriber Update). Consequence: seizures and brain swelling. Mitigation: fluids limited to thirst and a sodium check if headache, confusion or prolonged vomiting develops.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Opioid blockers (naloxone, naltrexone): blockade of the μ- and δ-opioid receptors that dermorphins and deltorphins activate; a case review reports naloxone use in one poisoning that resolved within an hour; no study tested the pairing (Sacco 2022). Consequence: weaker opioid-peptide effects; no harm reported.
- Thiazide diuretics (drugs that increase urinary sodium loss: hydrochlorothiazide, chlorthalidone), SSRIs (selective serotonin reuptake inhibitors, an antidepressant class: sertraline, citalopram) and carbamazepine: additive sodium lowering with SIADH. Consequence: severe hyponatremia. Mitigation: sodium checked before and after sessions.
- ACE inhibitors (angiotensin-converting enzyme inhibitors, which also slow bradykinin breakdown: lisinopril, ramipril) and sacubitril/valsartan: slower breakdown of bradykinin-like phyllokinin. Consequence: angioedema (deep swelling of lips, tongue or throat) and low blood pressure. Mitigation: urgent care for any lip or throat swelling.
- Blood-pressure-lowering drugs (amlodipine, losartan, metoprolol), PDE5 inhibitors (erectile-dysfunction drugs that widen blood vessels: sildenafil, tadalafil) and nitrates (chest-pain drugs that widen vessels: nitroglycerin): additive vessel widening with phyllokinin and phyllomedusin. Consequence: low blood pressure and fainting. Mitigation: lying down during sessions.
- Opioids (oxycodone, morphine, methadone), benzodiazepines (sedative anti-anxiety drugs: alprazolam, diazepam), gabapentinoids (nerve-pain drugs: gabapentin, pregabalin) and alcohol: additive sedation with dermorphins and deltorphins. Consequence: drowsiness, fainting and slowed breathing. Mitigation: no sedative use on session day.
- Digoxin and QT-prolonging drugs (sotalol, amiodarone, ondansetron): vomiting-induced low potassium and fast heart rate. Consequence: dangerous heart-rhythm disturbances. Mitigation: potassium and ECG checked beforehand.
- Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen): reduce kidney water excretion and blood flow. Consequence: worsened hyponatremia and kidney injury after dehydrating vomiting. Mitigation: no NSAID use on session day.
- Over-the-counter decongestants (pseudoephedrine, phenylephrine): additive heart-rate and blood-pressure swings. Consequence: palpitations and heart strain. Mitigation: no decongestant use on session day.
- Kratom (Mitragyna speciosa) supplements: opioid-receptor activation additive with dermorphins. Consequence: sedation and slowed breathing. Mitigation: no kratom use on session day.
- Blood-pressure-lowering supplements (beetroot nitrate, L-arginine, L-citrulline): additive vessel widening. Consequence: low blood pressure and fainting. Mitigation: no use on session day.
- Licorice (glycyrrhizin) and stimulant laxatives (senna): additive potassium loss alongside vomiting. Consequence: heart-rhythm disturbances. Mitigation: potassium checked beforehand and both stopped in the week before a session.
- Ayahuasca, 5-MeO-DMT (a short-acting psychedelic from toad venom) and rapé (tobacco snuff) in combined ceremonies: additive vomiting, fluid loss and heart strain. Consequence: dehydration, low sodium and arrhythmia. Mitigation: no same-week co-use.
- Fasting, colon cleanses and saunas: add sodium and fluid loss to vomiting. Consequence: hyponatremia or dehydration. Mitigation: normal meals and salt intake around sessions.
- Cancer chemotherapy and immunotherapy (cisplatin, gemcitabine, pembrolizumab): overlapping inflammatory and organ toxicity. Consequence: a body-wide inflammatory reaction that can mimic tumor progression and complicate treatment decisions. Mitigation: oncology team informed before any session.
Populations who should avoid Kambô:
- Pregnancy: a systematic review reports traditional use to induce abortion (Sacco 2025); no human outcome data, so harm is inferred from smooth-muscle and blood-pressure effects.
- Heart disease (coronary disease, LVH, arrhythmia, unexplained fainting): sudden death occurred in a user with LVH and coronary atheroma (fatty plaque in heart arteries) (Aquila 2018).
- Serum sodium below 135 mmol/L or use of sodium-lowering drugs: inferred from the SIADH mechanism; the threshold is the lower limit of the standard reference range.
- Seizure disorders: inferred from seizures in hyponatremic cases; no group data.
- Psychotic or bipolar disorders: inferred from psychosis case reports (Roy 2018); no group data.
- Active cancer: a severe inflammatory reaction occurred in a patient with cholangiocarcinoma (bile-duct cancer) (Peleg Hasson 2021).
- Liver or kidney disease: inferred from hepatitis and kidney-injury case reports; no group data.
- Esophageal disease or recent chest or abdominal surgery: inferred from esophageal rupture during violent vomiting; no group data.
- History of angioedema or hereditary angioedema: inferred from bradykinin-receptor activation; no human data.
- Children and people of low body weight: inferred from the higher dose per body mass, as a systematic review notes (Sacco 2025); no human data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- No water loading: Fluids limited to thirst, rather than the 3.5–6 liters drunk in three cases of a case review (Sacco 2022), mitigate SIADH-related hyponatremia, seizures and brain swelling.
- Pre-session screening: A baseline ECG, serum sodium and potassium, kidney and liver tests, and a pregnancy test identify excess risk of arrhythmia, sudden cardiac death, hyponatremia and pregnancy loss before any exposure.
- Few application points: One test point, then only a few points per session, limits peptide dose and so mitigates the acute purge, fainting and hyponatremia; many side effects are thought to be dose dependent (Medsafe Prescriber Update).
- Emergency threshold: Urgent care for severe vomiting, fainting or facial swelling (Better Health Channel fact sheet), and for seizure, chest pain, confusion or symptoms beyond 1 hour, mitigates delayed treatment of hyponatremia, arrhythmia and esophageal rupture.
- Sodium stop rule: A serum sodium below 135 mmol/L at baseline, or any post-session value below it with symptoms, stops further sessions and prompts medical care, mitigating progressive hyponatremia and brain swelling.
- No combined ceremonies: Avoiding ayahuasca, 5-MeO-DMT, rapé and fasting in the same week mitigates additive vomiting, fluid loss and heart strain.
- Session spacing: Weeks between sessions, rather than frequent repeated use, mitigate cumulative toxicity; psychosis followed frequent use in one case (Roy 2018).
- Supervised application only: An attending person with an emergency plan mitigates unattended collapse and overdosing; do-it-yourself kits are sold in the UK (Lang 2026).
- Medication review: Identifying thiazides, SSRIs, ACE inhibitors, opioids and blood-pressure drugs before a session mitigates the theoretical interactions listed above.
- Burn-site care: Small superficial burns kept clean and covered mitigate wound infection and scarring at application points.
Therapeutic Protocol
Other parameters without a citation (e.g., timing, cycling, titration steps) reflect common practice.
- Standard Western session: A practitioner burns 1–20 small points (mean 6.3) and applies reconstituted secretion; acute effects last 15–60 minutes in most users (Majić 2021); the survey authors also recount that the urban form follows rubber tapper Francisco Gomes’s re-invention.
- Traditional indigenous session: Three to five small burns on the upper arm or lower leg with little ceremony, followed by dragon’s blood (Croton lechleri) sap as an antiseptic (Conversation article).
- Neo-shamanic ceremony: Kambô combined with rapé, sananga (plant-extract eye drops), prayer cards and meditative music after a three-day cleanse (Science-Based Medicine post).
- Practitioner approach: Caitlin Thompson, a practitioner who earns income from sessions, describes kambô for Lyme disease and autoimmune conditions, prepared with intention-setting (Outliyr podcast).
- Regulatory position: No medical dosing protocol exists; Australia prohibits supply and use (Poisons Standard October 2026), and Medsafe states kambô is not an approved medicine in New Zealand (Medsafe Prescriber Update).
- Dose unit: The amount of secretion per point is not standardized, and the number of points did not significantly correlate with the duration of the acute reaction (Majić 2021).
- Preparation: 62.95% of surveyed users followed a preparation diet, and some fasted or drank large amounts of water (Majić 2021).
- Application site: Upper limbs in men and lower limbs in women by tradition, per a case review (Sacco 2022).
- Time of day: Sessions are commonly held in the morning on an empty stomach, so that vomiting brings up fluid rather than food and recovery occurs during the day.
- Half-life: No human data exist; dermorphin’s elimination half-life was 0.76 hours in horses (Robinson 2015), consistent with short-lived acute effects.
- Single versus split dosing: All points are applied in one sitting; some practitioners add points during the session when the reaction is mild.
- Genetic polymorphisms: No pharmacogenetic data guide point number; OPRM1 and long-QT gene variants are untested modifiers of response.
- Sex: No sex-specific dosing data exist; 9 of 11 poisoning cases in a case review were women (Sacco 2022).
- Age: Surveyed users averaged 38 years (Majić 2021); no response or dosing data exist for older adults.
- Baseline biomarkers: No biomarker predicts response; sodium, potassium and ECG findings shape eligibility rather than dose.
- Pre-existing conditions: Heart disease, seizure disorders, psychotic disorders, active cancer and pregnancy define exclusion rather than dose adjustment (see Key Interactions & Contraindications).
- Series pattern: Practitioners commonly describe an initial series of about three sessions within a month, followed by occasional sessions.
Discontinuation & Cycling
- Short-term, episodic use: Kambô is used in occasional sessions, not as a lifelong daily intervention; most surveyed users had more than one session, and 81.86% had their last within 12 months (Majić 2021).
- Withdrawal effects: No withdrawal syndrome has been described; the opioid peptides act for minutes, making physical dependence unlikely, though this has not been studied.
- Tapering: Not applicable; stopping requires no taper because use is intermittent.
- Cycling: No evidence shows that cycling maintains any benefit; practitioner session series are untested, and frequent repeated use preceded psychosis in one case (Roy 2018).
- After-effects: Drowsiness and apathy follow the acute phase (Medsafe Prescriber Update); separately, 26.17% of respondents reported longer-term, predominantly positive effects lasting 1–6 months (Majić 2021).
Sourcing and Quality
- Product form: Kambô is sold as dried secretion on bamboo sticks and reconstituted with water before use (Conversation article).
- Identity and purity: A systematic review warns that secretions of other amphibians may be substituted (Sacco 2025), and a case review found kambô peptides identified in only one of 11 poisoning investigations (Sacco 2022).
- Third-party testing: No certification body or third-party testing program covers kambô sticks; a systematic review notes the specialized mass spectrometry needed to identify the peptides is not universally available (Sacco 2025).
- Reputable brands: No reputable brand, pharmaceutical source or compounding pharmacy exists; kambô is prohibited in Australia (Poisons Standard October 2026) and not an approved medicine in New Zealand (Medsafe Prescriber Update).
- Practitioner source: 74.09% of surveyed sessions were given by Western practitioners, 13.47% by indigenous practitioners and 3.89% were self-administered (Majić 2021); practitioner training is unregulated.
- What to look for: Training is private; the International Association of Kambo Practitioners (IAKP website) sells courses covering safety and contraindications, so its certification carries a revenue interest. Screening for heart disease, pregnancy and sodium-lowering drugs, and no water loading, mark a safety-oriented practitioner.
- Legal sourcing: Sale, supply and use are prohibited in Australia (Poisons Standard October 2026); importing or carrying sticks across borders may breach local law.
- Animal welfare and conservation: Frogs are captured, tied and stressed to release the secretion (Medsafe Prescriber Update), and a review reports that indigenous communities fear misuse of the species (Nogueira 2022).
Practical Considerations
- Time to effect: Acute effects begin within minutes and usually last 15–60 minutes; users’ conviction of benefit rose in the days after a first session, and longer-term effects lasted 8–30 days in 24.61% and 1–6 months in 26.17% of respondents (Majić 2021).
- Common pitfalls: Drinking liters of water recurs across poisoning cases in a case review (Sacco 2022); one patient fasted for a week before hyponatremic seizures (Jauregui 2025), another took ayahuasca before kambô (Campodónico 2019), and self-application preceded a severe polyneuropathy (Mantilla-Pardo 2026).
- Regulatory status: Australia lists kambô in Schedule 10 of the Poisons Standard (Poisons Standard October 2026); in New Zealand it is not an approved medicine (Medsafe Prescriber Update).
- Cost and accessibility: Kambô is neither exceptionally expensive nor hard to find; one US ceremony cost $150 (Science-Based Medicine post), and sticks are sold online.
- Recognition in emergencies: A line of small burns is a key clue for clinicians (Leban 2016), because toxicology screening identified kambô peptides in only one of 11 cases in a case review (Sacco 2022).
Interaction with Foundational Habits
- Sleep: Indirect. Drowsiness and apathy follow the acute phase (Medsafe Prescriber Update); insomnia was a rare new complaint in the survey (Majić 2021). Sauvagine’s stress-hormone activation makes evening sessions a plausible sleep disruptor; morning sessions keep the recovery period in daytime.
- Nutrition: Potentiating risk. Ritual fasting and restrictive diets lower sodium intake and amplify SIADH; one patient ate only celery and water for a week before hyponatremic seizures (Jauregui 2025). Normal meals and salt intake around sessions counter this; no nutrient depletion beyond vomiting losses is documented.
- Exercise: Indirect, not studied. Strenuous exercise on session day adds sweat sodium loss and heart strain to vomiting-induced fluid shifts, the same water-and-sodium mechanism behind exercise-associated hyponatremia. Rest for the remainder of the session day avoids this overlap; no effect on training adaptation is documented.
- Stress management: Direct. Sauvagine activates CRF receptors acutely, and 17.10% of respondents felt anxiety or panic during sessions while 18.13% felt joy; 31.35% meditated beforehand (Majić 2021). Reported longer-term well-being gains are uncontrolled.
Monitoring Protocol & Defining Success
Before a first session, baseline testing covers the safety checks that identify excess risk: serum sodium and potassium, kidney and liver function, creatine kinase, a resting ECG, and a pregnancy test in anyone who could be pregnant. No biomarker of benefit exists, so laboratory monitoring serves safety only.
Ongoing monitoring follows the session schedule: sodium within 2–6 hours after any session with persistent vomiting, headache, confusion or weakness; a repeat panel at 24–48 hours if symptoms continue; and the full baseline panel before each new session series, or every 3–6 months for repeated users. Success is judged by the qualitative markers below, tracked against the individual’s own pre-session baseline.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Serum sodium | 135–145 mmol/L (standard reference range) | Safety check: a low value stops use | Baseline and after symptomatic sessions; pair with plasma and urine osmolality (concentration of dissolved particles) to identify SIADH (Leban 2016); no fasting needed |
| Serum potassium | 3.5–5.0 mmol/L (standard reference range) | Safety check: a low value stops use | A case review found low potassium in several poisonings (Sacco 2022); pair with magnesium |
| Resting ECG (rhythm and QTc) | Sinus rhythm; QTc below 450 ms in men and 460 ms in women (AHA/ACCF/HRS cutoffs for a prolonged QTc) | Safety check: an abnormal rhythm or prolonged QTc stops use | Cutoffs from the American Heart Association, American College of Cardiology Foundation and Heart Rhythm Society statement (Rautaharju 2009); the conventional ECG reference range uses the same upper limits; baseline tracing; repeat if palpitations or fainting occur after a session |
| ALT | Up to about 40 U/L (standard reference range; laboratory-specific) | Safety check: a rise stops use | ALT (alanine aminotransferase, a liver enzyme); pair with AST (aspartate aminotransferase, a liver and muscle enzyme); toxic hepatitis case (Pogorzelska 2017) |
| Serum creatinine | About 0.6–1.2 mg/dL (standard reference range; sex- and laboratory-specific) | Safety check: a rise stops use | Pair with eGFR (estimated glomerular filtration rate, a calculated kidney-filtration measure); kidney injury case (Alvarez-Boizo 2025) |
| Creatine kinase | About 30–200 U/L (standard reference range; laboratory-specific) | Safety check: a marked rise signals muscle breakdown and stops use | Check after seizures or prolonged weakness; reached 107,216 IU/L in one case (Campodónico 2019) |
| hCG | Negative (standard reference range) | Safety check: a positive result stops use | hCG (human chorionic gonadotropin, the pregnancy hormone); urine or serum test before each session |
- Well-being and mood: self-rated life satisfaction, mood and anxiety before and in the weeks after a session.
- Substance use: frequency of alcohol, tobacco and recreational drug use compared with baseline.
- Energy and sleep: daytime energy, fatigue and sleep quality over the following week.
- Persistent symptoms: any weakness, numbness, confusion, behavioral change, chest pain or swelling lasting beyond the session day.
- Burn-site healing: redness, discharge or scarring at application points.
Emerging Research
- Completed retreat survey: “Entheogen Resurgence”, an observational survey of 102 retreat participants including kambô users (NCT05042765), completed January 2022 with no registry results posted. Its published report covers only willingness to join research on ritual psychoactive substances (95.5% favored such research), not kambô outcomes, leaving the well-being evidence unchanged (Kirk 2023).
- No registered interventional trials: ClinicalTrials.gov lists no interventional trial of kambô or its peptides. A practitioner-researcher reports human studies underway (Outliyr podcast), none with an NCT ID; her retrospective review of 147 clients found no severe adverse events (Thompson 2022). Positive controlled data could lift well-being above Low; null data would leave benefits anecdotal.
- Peptide drug leads: Reviews describe dermaseptins as preclinical antimicrobial and antitumor leads (Bartels 2019) and amphibian opioid peptides as models for new pain drugs (Negri 2000). Success would yield purified drugs, strengthening interest in the chemistry without validating the ritual.
- Repurposing isolated peptides for pain: Two reviews propose new studies of intrathecal dermorphin for post-surgical and palliative pain and of ceruletide for cancer pain (Keppel Hesselink 2018; Keppel Hesselink 2020). Positive trials would firm up isolated-peptide pain relief; failures would weaken that benefit.
- Harm surveillance: A systematic review calls for epidemiological and toxicological surveillance and better peptide detection (Sacco 2025). Incidence data could show serious harms are rarer than case reports suggest, weakening the case against kambô, or more common, strengthening it.
- Home-use kits: A 2026 BMJ feature examined do-it-yourself kambô kits sold in the UK (Lang 2026); growth of unsupervised use may change the harm profile that future case series report.
Conclusion
Kambô is a frog skin secretion rubbed into small skin burns. It delivers a mixture of strong morphine-like, blood-pressure-lowering, gut-stimulating and stress-hormone-like compounds that produce a violent but usually brief purge. For health-focused adults considering it, the evidence for benefit is thin. The human data come from surveys of self-selected users who describe better well-being and less use of alcohol and drugs afterwards, with nothing to separate the effect of the secretion from expectation, ritual and setting. Some single compounds from the secretion relieve pain, or kill microbes and tumor cells, in early clinical and laboratory work, but they were tested as purified drugs, not as kambô.
The harm record is also built from individual case reports rather than trials, yet it is consistent and serious: dangerous drops in blood sodium, often worsened by heavy water drinking during the ritual, seizures, sudden heart-related death, tearing of the esophagus from vomiting, liver and kidney injury, immune attacks on muscle and nerves, and lasting psychiatric change. Because nobody counts how many people use kambô, how often these events happen is unknown. Much of the favorable testimony comes from practitioners who earn money from ceremonies, while most published harm reports come from emergency and death-investigation settings that see only the worst outcomes. The product itself is untested and unstandardized, and its legal status ranges from unregulated to prohibited.